EGFR expression

Findings on EGFR mutations were consistent with the national and international literature. However, PD-L1 expression rates were higher than those typically reported in Brazilian studies, highlighting regional variation in biomarker prevalence.

These findings demonstrate a distinct surface antigen landscape in testicular GCTs, with CLDN6, EGFR, and TROP2 emerging as leading candidates for further translational evaluation. Enrichment of these targets highlights antigenic heterogeneity within GCTs and supports further validation in appropriate disease settings including metastatic, post-treatment, and relapsed or refractory disease.

P1, N=95, Not yet recruiting, National Cancer Institute (NCI)

These findings suggest that CD44 expression is statistically associated with EGFR, STAT3, and FAS expression in OSCC. Although a direct correlation with clinicopathological aggressiveness was not evident in this study, the co-expression of CD44 with these molecular markers provides a basis for the hypothesis that CSC properties may be interrelated with signal transduction and lipid metabolic reprogramming in oral cancer cells.

The frequency of H. pylori infection and HER2 over-expression occurred more frequently in MSI positive GCs. In particular, HER2 overexpression was more evident in MSI-EGC. MSI-EGC is a group of diseases with unique molecular biological characteristics and may show rapid tumor growth potential, so special treatment measures may be needed.

In IMvigor210, immunoproteasome-high patients achieved a 3.2-fold higher response rate to atezolizumab (19.8% vs 6.2%; p=0.010). Single-cell analysis confirmed that tumor-intrinsic immunoproteasome expression correlated with increased CD8+ T cell infiltration (p=0.0014) and total immune fraction (p=0.0002). The 4-gene immunoproteasome signature demonstrates robust prognostic and predictive value across bulk sequencing, clinical trial, and single-cell platforms, warranting prospective validation as an immunotherapy biomarker.

Importantly, early clinical studies demonstrated that the EGFR-targeted ADC MRG003 and the TROP2-targeted ADC Sac-TMT showed notable efficacy in patients with refractory ACC and high expression of these targets. This pioneering study introduces a biomarker-based stratification system, categorizing ACC patients by histological subtype and target expression profiles, EGFR/TROP2 for non-solid ACC and B7-H4/Nectin-4 for solid ACC, to inform ADC therapy decisions.

This study confirmed that the combination of attenuated S. typhimurium L-forms and lentiviral shRNA-HOTAIR significantly enhanced the suppression of tumor growth and aggressiveness in murine breast cancer. These findings supported the potential of this combined strategy of attenuated ST L-forms and lentiviral shHOTAIR as a novel and more effective bio-therapeutic approach for bacterial-mediated breast cancer therapy.

Moreover, bakuchiol was also found to exhibit a synergistic effect against TNBC cells in association with the standard chemotherapeutic drug doxorubicin, thereby enhancing its therapeutic efficacy. These findings highlight bakuchiol as a promising HSP90-targeting natural compound with potential therapeutic benefit against TNBC, therefore making it a crucial lead for further research.

Histopathological analysis confirmed that therapeutic efficacy was driven by a significant reduction in EGFR protein levels. Our findings establish Hsp90-mediated stabilization of monomeric EGFR as a novel resistance mechanism and provide a translational rationale for employing low-dose Hsp90 inhibition in combination with cetuximab to improve clinical outcomes for HNSCC patients currently lacking effective targeted options.

Quantitative analysis revealed that EGFR-BsTe secretion abrogated EGFR upregulation and enhanced B7-H3 downregulation in a target-dependent manner; however, efficacy was diminished when the CAR-Target (B7-H3) was absent on a substantial fraction of tumor cells. Our findings suggest that arming B7-H3 CAR-T cells with EGFR-targeting bispecific engagers represents a promising strategy to overcome antigen heterogeneity and improve therapeutic outcomes for GBM patients.

P2, N=30, Not yet recruiting, HuiKai Li